Zomedica Corp. (ZOMDF) Stock Price & How to Invest

Last updated November 2026

Short answer

Zomedica (ZOMDF) is an Ann Arbor animal-health company selling PulseVet shockwave systems, Assisi devices and TRUFORMA diagnostics to vets. It reported record third-quarter 2026 revenue of ~$9.9 million, up ~22%, a net loss that shrank ~48% to ~$3.2 million, and ~$40.9 million of cash and securities, but it still loses money. At ~$0.08 and ~980 million shares, it carries a market value of roughly ~$80 million on the OTCQB, and the shares are down about 26% in 2026.

ZOMDF stock price

As of 2026-11-20, Zomedica Corp. (ZOMDF) last closed at $0.0800, down 27.3% over the past year. Over the past 52 weeks it has traded between $0.0740 and $0.1540.

ZOMDF last close
$0.0800
1 day
-3.61%
1 month
+2.56%
1 year
-27.27%
52-week range
$0.0740 to $0.1540
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Zomedica Corp.'s investor relations page. Walnut is informational, not investment advice.

ZOMDF key stats

At $0.08 on November 20, 2026, Zomedica Corp. (ZOMDF) has a market cap of $78M.

Market cap
$78M
Price to book
0.8
Beta
1.32

Market cap, P/E and yield are measured at the $0.08 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Zomedica Corp. (ZOMDF)?

The last two weeks for Zomedica Corp., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • ZOMDF closed at $0.08 on November 20, 2026, down 18.4% over the past five trading days (from $0.10).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Zomedica Corp. (ZOMDF) do?

Zomedica Corp. is an Alberta-incorporated, Michigan-based animal-health company that sells therapeutic devices and point-of-care diagnostics to equine and companion-animal veterinarians. Its largest line is the PulseVet electrohydraulic shockwave system, acquired in 2021, which treats tendon, ligament, bone and wound conditions and earns recurring revenue from replacement applicators called trodes. It also sells Assisi pulsed electromagnetic devices, VETIGEL hemostatic gel, the TRUFORMA diagnostic platform, VETGuardian remote vital-signs monitoring and TRUVIEW digital cytology. A third segment, Development Services, began in the second half of 2025 and sells engineering, development and contract manufacturing work to outside partners. In September 2026 it announced a strategic partnership with Veterinary Study Groups (VMG) to bring its technologies to independent practices.

The business is small but no longer tiny. Revenue was ~$32.0 million in 2025, including a record ~$10.5 million fourth quarter, and ~$28.2 million in the first nine months of 2026, up ~31%. Third-quarter 2026 revenue, reported November 4, was a third-quarter record of ~$9.9 million, up ~22% from ~$8.1 million, with Therapeutic Devices at ~$7.2 million (up ~7%), Diagnostics at ~$1.6 million (up ~113%) and Development Services at ~$1.1 million. Excluding Development Services, revenue grew ~18%. Consumables rose ~26% to ~$6.8 million. Gross margin ran ~61% in the quarter, and operating expenses fell ~21% to ~$9.5 million. The company still lost ~$3.2 million in the quarter, down from ~$6.1 million a year earlier, and ~$11.5 million over nine months. In 2025 it booked ~$55.8 million of non-cash impairment charges, writing off all goodwill on PulseVet and Assisi after its share price fell.

The stock's history explains much of its current price. Zomedica raised large sums during the 2021 retail trading wave and ended up with ~980 million common shares outstanding. NYSE American suspended trading on March 4, 2025, under its rule on shares trading at abnormally low prices, and the shares moved to the OTCQB as ZOMDF the next day. The company still files 10-Ks and 10-Qs with the SEC. At ~$0.08, the market value is roughly ~$80 million against ~$40.9 million of cash and available-for-sale securities at September 30, 2026, and Yahoo puts the shares at about 0.77 times book value. Management's second-quarter 10-Q said existing cash was sufficient for the next 12 months and beyond and reported no pending legal proceedings, and the third-quarter release said the company is well positioned to close the year strong without giving numerical guidance.

What's driving Zomedica Corp. (ZOMDF)?

1. PulseVet consumables and the installed base

Therapeutic Devices produced ~$7.2 million of third-quarter 2026 revenue, about 73% of the total, at a ~64% segment gross margin. The model resembles a razor-and-blade business: each PulseVet system sold adds a clinic that buys replacement trodes, and consumables revenue rose ~26% to ~$6.8 million in the quarter while capital sales of PulseVet and VETGuardian systems came to ~$2.0 million. PulseVet began in equine sports medicine and has been extended to small animals through the X-trode handpiece. How many new systems are placed each quarter, and how heavily existing clinics use them, largely determines whether this segment keeps growing faster than the ~7% it managed in the third quarter.

2. TRUFORMA diagnostics and the Boehringer collaboration

Diagnostics revenue was ~$1.6 million in the third quarter of 2026, up ~113%, after ~$1.4 million in the second quarter (up ~77%). TRUFORMA is a bulk acoustic wave sensor platform for in-clinic tests, including equine assays, and Zomedica bought the sensor maker's biotechnology unit from Qorvo in 2023 to control its supply. Management credits a commercial collaboration with Boehringer Ingelheim Animal Health and new international distributors for the acceleration. The segment is still small next to the incumbents in veterinary diagnostics, so growth from a ~$5-6 million annual base can look large in percentage terms while staying modest in dollars.

3. Development Services as a new revenue line

Development Services, launched in the second half of 2025, sells Zomedica's engineering, development and manufacturing capacity to partners in both animal and human health. It produced ~$3.1 million in 2025, ~$3.4 million in the first half of 2026 and ~$1.1 million in the third quarter, a step down from ~$1.4 million in the second, and it explains the gap between ~22% reported growth and ~18% growth in the core product lines. This revenue uses capacity the company already pays for, which helps operating leverage, but it is project-based. Contract work can arrive in lumps and end when a program finishes, so it may prove less predictable than trode reorders.

4. Cost cuts and the path toward breakeven

Operating expenses fell ~21% to ~$9.5 million in the third quarter of 2026, after a ~20% drop to ~$10.1 million in the second. Quarterly cash burn dropped to ~$3.2 million, down ~32% from a year earlier, after ~$18.1 million of burn for all of 2025. The third-quarter net loss narrowed to ~$3.2 million from ~$6.1 million a year earlier, and adjusted EBITDA loss to ~$1.6 million from ~$3.9 million. With ~$40.9 million of liquidity, burn at the current pace would leave several years of runway. Management describes cash-flow breakeven as its stated goal; it has not yet reported a profitable quarter.

What are the risks to Zomedica Corp. (ZOMDF)?

The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. Cash and securities fell to ~$40.9 million at September 30, 2026 from ~$44.1 million in June as the company funded losses, and a slower burn reduction would shorten its runway. The share count is very large at ~980 million, so even small per-share price moves change the market value meaningfully, and any future equity raise at today's prices would dilute heavily. OTCQB trading usually means thinner liquidity, wider spreads and less analyst coverage than an exchange listing; no analysts publish estimates on Yahoo. Shareholders rejected the executive pay proposal at the June 2026 meeting, a sign of investor frustration, and the stock is down about 26% over the year to November 20, 2026. Commercially, PulseVet faces other shockwave and rehabilitation devices, TRUFORMA competes with much larger diagnostic suppliers, and Development Services revenue depends on a few project contracts and already dipped quarter over quarter. Finally, the 2025 impairments show that past acquisitions have not earned back what was paid for them.

Is ZOMDF a buy or a sell?

We give no verdict on Zomedica Corp.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. PulseVet consumables and the installed base. Therapeutic Devices produced ~$7.2 million of third-quarter 2026 revenue, about 73% of the total, at a ~64% segment gross margin.

The case against. The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year.

Read the full bull and bear case on ZOMDF, including what would have to change to break either one. Walnut is not an investment adviser.

How is Zomedica Corp. (ZOMDF) valued?

Market cap, P/E and dividend yield at today's price are in the ZOMDF key stats above. The business figures below come from Zomedica Corp.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$38.7 million; Q3 2026 ~$9.9 million, up ~22%
  • Net loss (TTM): ~$16 million; Q3 2026 ~$3.2 million (vs ~$6.1 million)
  • Gross margin (Q3 2026): ~61%
  • Cash + securities (Sep 30, 2026): ~$40.9 million
  • Shares outstanding: ~980 million

As of November 2026: Trailing revenue is derived from ~$32.0 million in 2025 plus ~$28.2 million in the first nine months of 2026, less ~$21.6 million in the first nine months of 2025. At ~$0.08 a share, the market value of ~$80 million is about ~2.1 times sales and below book value (Yahoo shows ~0.77 times book). Subtracting ~$40.9 million of liquidity leaves an enterprise value near ~$39 million, about ~1.0 times sales. Because the company is unprofitable, earnings-based multiples do not apply.

Who competes with Zomedica Corp. (ZOMDF)?

Veterinary diagnostics leaders

IDEXX Laboratories, Zoetis and Antech (part of Mars) dominate in-clinic analyzers and reference labs, with installed bases in tens of thousands of practices. TRUFORMA competes for the same bench space and test budgets. Zomedica's diagnostics revenue of roughly ~$5-6 million a year is a small fraction of what these companies sell in a day.

Shockwave and rehabilitation devices

PulseVet competes with other veterinary extracorporeal shockwave systems, including European makers, and with alternative rehabilitation tools such as therapeutic lasers, PEMF devices and regenerative injections. Zomedica's edge is a long equine track record and a recurring trode business; competition shows up as price pressure and clinic choice between modalities.

Animal-health device and monitoring suppliers

VETGuardian monitoring, VETIGEL and Assisi devices sit in crowded categories served by larger distributors and diversified animal-health groups such as Covetrus, Dechra and Elanco channel partners. These rivals have broader catalogs and sales forces, which matters because vet practices often prefer fewer suppliers.

What stocks are similar to Zomedica Corp. (ZOMDF)?

Other names that sit close to ZOMDF: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Zomedica Corp. (ZOMDF)

There are three common ways to get ZOMDF exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ZOMDF sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ZOMDF fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Zomedica Corp. (ZOMDF)

A real, growing veterinary device business with ~$38.7 million of trailing revenue and no going-concern warning in its latest filings, priced near ~$0.08 after a low-price NYSE American delisting, still unprofitable and heavily diluted, though losses have narrowed each quarter of 2026.

More on Zomedica Corp. (ZOMDF)

Whether ZOMDF is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ZOMDF a buy or a sell?, and where the stock could go from here in the ZOMDF stock forecast.

For income investors, whether ZOMDF pays a dividend and how the payout looks is covered in does ZOMDF pay a dividend? And to weigh ZOMDF against a peer, read the full side-by-side comparisons: ZOMDF vs ZTS and ZOMDF vs HNGE.

Wondering how ZOMDF fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Zomedica Corp.

Ask Walnut's AI anything about ZOMDF and see how it fits what you own.

FAQ

What does Zomedica do?

+

Zomedica sells therapeutic devices and point-of-care diagnostics to veterinarians who treat horses, dogs and cats. Its biggest product is the PulseVet shockwave system, which treats musculoskeletal injuries and wounds and generates repeat revenue from replacement applicators called trodes. It also sells Assisi pulsed electromagnetic devices, VETIGEL to stop bleeding, the TRUFORMA diagnostic testing platform, VETGuardian remote vital-signs monitoring and TRUVIEW digital cytology. Since the second half of 2025 it has also run a Development Services segment that sells engineering and contract manufacturing work to partners in animal and human health. The company is incorporated in Alberta, Canada, is headquartered in Ann Arbor, Michigan, and had ~141 employees at the end of 2025, according to its annual report.

Why is Zomedica traded as ZOMDF instead of ZOM?

+

Zomedica used to trade on NYSE American as ZOM. On March 4, 2025, NYSE American suspended trading and began delisting proceedings under its rule on shares that trade at abnormally low prices for an extended period, after the stock had spent a long time well below $1. The shares moved to the OTCQB Venture Market the next morning under the ticker ZOMDF, and in August 2025 the company registered its common shares under Section 12(g) so it remains an SEC reporting company. Zomedica said at the time that the move did not change its operations. It still files 10-K and 10-Q reports and holds annual meetings. Trading on the OTCQB typically comes with lower volume and wider bid-ask spreads than a national exchange.

How much revenue does Zomedica make?

+

Zomedica reported ~$32.0 million of revenue for 2025, up from the prior year, including a record ~$10.5 million in the fourth quarter. In 2026 it reported ~$8.8 million in the first quarter, ~$9.5 million in the second and ~$9.9 million in the third, for ~$28.2 million over nine months, up ~31%. That puts trailing twelve-month revenue at roughly ~$38.7 million. Third-quarter revenue split into ~$7.2 million from Therapeutic Devices, ~$1.6 million from Diagnostics and ~$1.1 million from Development Services. The company says core growth excluding Development Services was ~18% in the third quarter.

Is Zomedica profitable?

+

No. Zomedica reported a net loss of ~$3.2 million in the third quarter of 2026 and ~$11.5 million over nine months, compared with ~$6.1 million and ~$77.3 million in the same periods of 2025. The 2025 figure was inflated by ~$55.8 million of non-cash impairment charges that wrote off all remaining goodwill on the PulseVet and Assisi units after the share price fell. The full-year 2025 net loss was ~$81.9 million. Excluding impairments, losses have been shrinking as operating expenses drop, and adjusted EBITDA loss was ~$1.6 million in the third quarter of 2026. Management says it is working toward cash-flow breakeven but has not given a date for reaching it.

Does Zomedica have enough cash, and is there a going-concern warning?

+

As of September 30, 2026, Zomedica reported ~$40.9 million of cash, cash equivalents and available-for-sale securities, down from ~$44.1 million at June 30, and Yahoo shows only ~$1.65 million of debt. Its second-quarter 10-Q contained no going-concern warning and stated that existing cash and securities were sufficient to fund expected needs for the next 12 months and for the longer term, and the third-quarter release did not raise one. Quarterly cash burn was ~$3.2 million in the third quarter of 2026, down from ~$18.1 million for all of 2025. That pace implies several years of runway, although the company also notes that business development activity could use some of its liquidity and that plans can change.

How many shares does Zomedica have, and why is the price so low?

+

Zomedica had ~979.9 million common shares outstanding as of August 2026, according to its second-quarter 10-Q cover. The large count dates mostly from equity raises during 2021, when retail interest briefly made the stock a heavily traded name and the company sold shares to build a cash pile and fund acquisitions such as PulseVet. With that many shares, a market value of ~$80 million works out to roughly ~$0.08 a share. A low per-share price on its own says little about value; what matters is the market value compared with revenue, cash and losses. The company has not announced a share consolidation, and its 2026 annual meeting did not include one.

Is Zomedica facing any lawsuits?

+

Zomedica's annual report for 2025 and its second-quarter 2026 10-Q both list Legal Proceedings as none. The 10-Q also states that, as of August 5, 2026, the company was not aware of any pending or threatened material litigation claims. Searches did not turn up an active securities class action against Zomedica; several lawsuit notices that appear in search results concern Zoetis, a different and much larger animal-health company with a similar name. Separately, shareholders voted against the company's executive compensation in an advisory vote at the June 2026 annual meeting, roughly ~100 million shares for and ~129 million against. That vote is non-binding, but it signals shareholder dissatisfaction with how pay lines up with results.

How does Zomedica's valuation compare with its business?

+

At ~$0.08 per share and ~980 million shares, Zomedica's market value is roughly ~$80 million. That is about ~2.1 times trailing revenue of ~$38.7 million and below book value, at about 0.77 times on Yahoo's figures. Because the company holds ~$40.9 million of cash and securities and little debt, its enterprise value is near ~$39 million, or about ~1.0 times sales. Price-to-earnings does not apply because the company is losing money. For context, large veterinary companies such as IDEXX and Zoetis are profitable and trade at far higher multiples of sales, while small unprofitable device makers often trade at low multiples until they show they can reach consistent positive cash flow.

How did Zomedica do in its latest quarter?

+

Zomedica reported third-quarter 2026 results on November 4, 2026: record third-quarter revenue of ~$9.9 million, up ~22% year over year (~18% excluding Development Services), with Diagnostics up ~113% and consumables up ~26%. Operating expenses fell ~21% to ~$9.5 million, the net loss narrowed ~48% to ~$3.2 million, adjusted EBITDA loss was ~$1.6 million, and cash burn was ~$3.2 million. Liquidity stood at ~$40.9 million. The company gave no numerical guidance.

How has ZOMDF stock performed in 2026?

+

As of November 20, 2026 ZOMDF closed near ~$0.08, down about 26% year to date and over twelve months, within a 52-week range of roughly ~$0.07 to ~$0.158. The shares were roughly flat over the past month despite the record third-quarter revenue. Past performance does not predict future returns, and Walnut is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Zomedica Corp.'s investor relations page or your broker before making investment decisions.